BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 32294731)

  • 1. HEPATOCELLULAR CARCINOMA PATIENTS ARE ADVANTAGED IN THE CURRENT BRAZILIAN LIVER TRANSPLANT ALLOCATION SYSTEM. A COMPETING RISK ANALYSIS.
    Rodríguez S; Fleck AM; Mucenic M; Marroni C; Brandão A
    Arq Gastroenterol; 2020; 57(1):19-23. PubMed ID: 32294731
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liver transplantation for hepatocellular carcinoma: the MELD impact.
    Sharma P; Balan V; Hernandez JL; Harper AM; Edwards EB; Rodriguez-Luna H; Byrne T; Vargas HE; Mulligan D; Rakela J; Wiesner RH
    Liver Transpl; 2004 Jan; 10(1):36-41. PubMed ID: 14755775
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liver transplantation in the MELD era: a single-center experience.
    Sachdev M; Hernandez JL; Sharma P; Douglas DD; Byrne T; Harrison ME; Mulligan D; Moss A; Reddy K; Vargas HE; Rakela J; Balan V
    Dig Dis Sci; 2006 Jun; 51(6):1070-8. PubMed ID: 16865573
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liver transplant recipient survival benefit with living donation in the model for endstage liver disease allocation era.
    Berg CL; Merion RM; Shearon TH; Olthoff KM; Brown RS; Baker TB; Everson GT; Hong JC; Terrault N; Hayashi PH; Fisher RA; Everhart JE
    Hepatology; 2011 Oct; 54(4):1313-21. PubMed ID: 21688284
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A method for establishing allocation equity among patients with and without hepatocellular carcinoma on a common liver transplant waiting list.
    Vitale A; Volk ML; De Feo TM; Burra P; Frigo AC; Ramirez Morales R; De Carlis L; Belli L; Colledan M; Fagiuoli S; Rossi G; Andorno E; Baccarani U; Regalia E; Vivarelli M; Donataccio M; Cillo U;
    J Hepatol; 2014 Feb; 60(2):290-7. PubMed ID: 24161408
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Excess mortality on the liver transplant waiting list: unintended policy consequences and Model for End-Stage Liver Disease (MELD) inflation.
    Northup PG; Intagliata NM; Shah NL; Pelletier SJ; Berg CL; Argo CK
    Hepatology; 2015 Jan; 61(1):285-91. PubMed ID: 24995689
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduced priority MELD score for hepatocellular carcinoma does not adversely impact candidate survival awaiting liver transplantation.
    Sharma P; Harper AM; Hernandez JL; Heffron T; Mulligan DC; Wiesner RH; Balan V
    Am J Transplant; 2006 Aug; 6(8):1957-62. PubMed ID: 16771808
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liver transplantation and waitlist mortality for HCC and non-HCC candidates following the 2015 HCC exception policy change.
    Ishaque T; Massie AB; Bowring MG; Haugen CE; Ruck JM; Halpern SE; Waldram MM; Henderson ML; Garonzik Wang JM; Cameron AM; Philosophe B; Ottmann S; Rositch AF; Segev DL
    Am J Transplant; 2019 Feb; 19(2):564-572. PubMed ID: 30312530
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence and risk factors of hepatocellular carcinoma recurrence after liver transplantation in the MELD era.
    Sharma P; Welch K; Hussain H; Pelletier SJ; Fontana RJ; Marrero J; Merion RM
    Dig Dis Sci; 2012 Mar; 57(3):806-12. PubMed ID: 21953139
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proposal of a novel MELD exception point system for hepatocellular carcinoma based on tumor characteristics and dynamics.
    Bhat M; Ghali P; Dupont B; Hilzenrat R; Tazari M; Roy A; Chaudhury P; Alvarez F; Carrier M; Bilodeau M
    J Hepatol; 2017 Feb; 66(2):374-381. PubMed ID: 27751840
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of Wait-List Mortality Between Cholangiocarcinoma and Hepatocellular Carcinoma Liver Transplant Candidates.
    Ziogas IA; Hickman LA; Matsuoka LK; Izzy M; Montenovo MI; Rega SA; Feurer ID; Alexopoulos SP
    Liver Transpl; 2020 Sep; 26(9):1112-1120. PubMed ID: 32475062
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A model for dropout assessment of candidates with or without hepatocellular carcinoma on a common liver transplant waiting list.
    Toso C; Dupuis-Lozeron E; Majno P; Berney T; Kneteman NM; Perneger T; Morel P; Mentha G; Combescure C
    Hepatology; 2012 Jul; 56(1):149-56. PubMed ID: 22271250
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the Intention-to-Treat Benefit of Living Donation in Patients With Hepatocellular Carcinoma Awaiting a Liver Transplant.
    Lai Q; Sapisochin G; Gorgen A; Vitale A; Halazun KJ; Iesari S; Schaefer B; Bhangui P; Mennini G; Wong TCL; Uemoto S; Lin CC; Mittler J; Ikegami T; Yang Z; Frigo AC; Zheng SS; Soejima Y; Hoppe-Lotichius M; Chen CL; Kaido T; Lo CM; Rossi M; Soin AS; Finkenstedt A; Emond JC; Cillo U; Lerut JP
    JAMA Surg; 2021 Sep; 156(9):e213112. PubMed ID: 34259797
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increasing disparity in waitlist mortality rates with increased model for end-stage liver disease scores for candidates with hepatocellular carcinoma versus candidates without hepatocellular carcinoma.
    Goldberg D; French B; Abt P; Feng S; Cameron AM
    Liver Transpl; 2012 Apr; 18(4):434-43. PubMed ID: 22271656
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MELDEQ : An alternative Model for End-Stage Liver Disease score for patients with hepatocellular carcinoma.
    Marvin MR; Ferguson N; Cannon RM; Jones CM; Brock GN
    Liver Transpl; 2015 May; 21(5):612-22. PubMed ID: 25694099
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Living donor liver transplant versus cadaveric liver transplant survival in relation to model for end-stage liver disease score.
    Al Sebayel M; Abaalkhail F; Hashim A; Al Bahili H; Alabbad S; Shoukdy M; Elsiesy H
    Transplant Proc; 2015 May; 47(4):1211-3. PubMed ID: 26036556
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Consequences of the implementation of the Model for End-stage Liver Disease system for liver allocation in Brazil.
    Pestana RC; Baracat EI; Massarollo PC; Pereira LA; Szutan LA
    Transplant Proc; 2013; 45(6):2111-4. PubMed ID: 23747144
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of the Liver Transplant Waiting List in Our Center.
    Emek E; Yesim Kara Z; Demircan FH; Serin A; Yazici P; Sahin T; Tokat Y; Bozkurt B
    Transplant Proc; 2019 Sep; 51(7):2413-2415. PubMed ID: 31474297
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A new priority policy for patients with hepatocellular carcinoma awaiting liver transplantation within the model for end-stage liver disease system.
    Piscaglia F; Camaggi V; Ravaioli M; Grazi GL; Zanello M; Leoni S; Ballardini G; Cavrini G; Pinna AD; Bolondi L
    Liver Transpl; 2007 Jun; 13(6):857-66. PubMed ID: 17539006
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatocellular carcinoma patients are advantaged in the current liver transplant allocation system.
    Washburn K; Edwards E; Harper A; Freeman R
    Am J Transplant; 2010 Jul; 10(7):1643-8. PubMed ID: 20486906
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.